Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates

分组1 - Veracyte reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and compared to a loss of $0.12 per share a year ago, representing an earnings surprise of 1,100% [1] - The company achieved revenues of $114.43 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 14.04%, and up from $90.32 million year-over-year [2] - Veracyte has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 23.7% since the beginning of the year, while the S&P 500 gained 8.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $101.22 million, and for the current fiscal year, it is -$0.05 on revenues of $406.07 million [7] - The Medical - Instruments industry, to which Veracyte belongs, is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]